>>> FireEye reports EPS in-line, beats on revs; guides Q2 EPS in-line, revs in-l

FireEye reports EPS in-line, beats on revs; guides Q2 EPS in-line, revs in-line; guides FY18 EPS in-line, revs in-line (18.55 +0.17)
Reports Q1 (Mar) loss of $0.04 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($0.04); revenues rose 7.7% year/year to $199.07 mln vs the $193.91 mln Capital IQ Consensus.
Billings of $175.1 million, an increase of 21 percent from the first quarter of 2017, and slightly above our guidance range of $165 million to $175 million.1
Co issues in-line guidance for Q2, sees EPS of ($0.03)-$0.00, excluding non-recurring items, vs. ($0.01) Capital IQ Consensus Estimate; sees Q2 revs of $199-203 mln vs. $200.37 mln Capital IQ Consensus Estimate; sees Billings in the range of $180 million to $195 million.
Co issues in-line guidance for FY18, sees EPS of $0.00-0.04, excluding non-recurring items, vs. $0.02 Capital IQ Consensus Estimate; sees FY18 revs of $820-830 mln vs. $819.34 mln Capital IQ Consensus Estimate; sees Billings in the range of $815 million to $835 million.

>>> Square beats by $0.01, beats on revs; guides Q2 EPS below co

Square beats by $0.01, beats on revs; guides Q2 EPS below consensus, revs above consensus; guides FY18 EPS in-line, revs above consensus (48.66 +0.46)
Reports Q1 (Mar) earnings of $0.06 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.05; revenues rose 50.5% year/year to $307 mln vs the $293.07 mln Capital IQ Consensus.
Co processed $17.8 billion in GPV, up 31% year over year.
Co issues mixed guidance for Q2, sees EPS of $0.09-0.11, excluding non-recurring items, vs. $0.12 Capital IQ Consensus Estimate; sees Q2 revs of $355-360 mln, excluding non-recurring items, vs. $334.56 mln Capital IQ Consensus Estimate.
Co issues guidance for FY18, sees EPS of $0.44-0.48, excluding non-recurring items, vs. $0.45 Capital IQ Consensus Estimate; sees FY18 revs of $1.4-1.43 bln, excluding non-recurring items, vs. $1.35 bln Capital IQ Consensus Estimate.

>>> Kraft Heinz beats by $0.08, reports revs in-line

Kraft Heinz beats by $0.08, reports revs in-line (54.20 -1.50)
Reports Q1 (Mar) earnings of $0.89 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $0.81; revenues fell 0.3% year/year to $6.30 bln vs the $6.32 bln Capital IQ Consensus.
"The initial successes we're seeing in the marketplace, together with the strong investments we're making in marketing, new product innovation, and capability-building, give us increased confidence in delivering the top- and bottom-line growth we expect in 2018."

>>> CITRON RESEARCH IS BULLISH ON THE MOST SHORTED STOCK IN THE WORLD.


Alibaba on its way to $250
Citron Research believes the most compelling growth story in the market is also the world’s most heavily shorted stock.
The professionals at Citron have been shorting stocks for a combined 100 years and wonder: “Why be short the most compelling TAM situation in the history of the stock market?”
On Friday morning, we will see the release of Alibaba earnings and fiscal year 2019 revenue guidance and one of two things will happen:
  • Alibaba will exceed expectations on its quarter and guidance and could easily go over $200 as “the setup” (explained below) is in place
  • Alibaba will show lower operating margins than “sell side consensus” due to offensive, value creating investments which may give investors an opportunity to buy what could be the first trillion-dollar company at a cheap price.

>>> US Gapping down


Gapping down
In reaction to disappointing earnings/guidance:

  • SNAP -18.8%, DBD -14.9%, YUMC -11.2%, BLDP -9.4%, SSYS -8.4%, SKT -8.2%, PAYC -6.5%, GILD -6.3%, TRUP -5.8%, NBR -5.3%, BPI -4.1%, DENN -3.6%, JBT -3.4%, COHR -3.2%, YUM -3%, NCR -2.9%, NFX -2.8%, NUVA -2.8%, W -2.6%, VRSK -2.5%, EIX -2.3%, QUAD -2.1%, APC -1.9%, CHRW -1.8%, WATT -1.8%, CAMT -1.5%, HSC -1.5%, QUOT -1.3%, MITK -1.3%, ENLC -1.1%, MGPI -1.1%

Other news:

  • ESPR -21.3% (reported Q1 and positive top-line results from pivotal Phase 3 long-term safety study of bempedoic acid)
  • QURE -6.2% (commences offering of 4 mln ordinary shares)
  • KR -1.7% (on reports that Amazon is planning more Prime perks at Whole Foods, including 10% off already discounted items)
  • BTX -1.4% (announced the award of a grant of approximately $386,000 from the NIH)
  • KPTI -0.8% (proposes public offering of $125 in shares of common stock)

Analyst comments:

  • CMI -2.8% (downgraded to Sell from Neutral at UBS)
  • NUVA -2.8% (downgraded to Market Perform from Outperform at BMO Capital Markets)
  • PCAR -1% (downgraded to Neutral from Buy at UBS)
  • ULTA -1% (downgraded to Hold from Buy at Loop Capital)

>>> US Gapping up


Gapping up
In reaction to strong earnings/guidance:

  • CRAY +12.5%, SFLY +10.7%, NANO +10.3%, SQNS +9.4%, ENPH +8.9%, ZEN +8.6%, LITE +8.3%, CYH +7.6%, EVTC +7.3%, MTSI +7.2%, BRKS +7.2%, JNPR +7.1%, FTR +6.4%, CRTO +5.5%, PBI +5.2%, MBUU +5%, AAPL +4.5%, NVO +4.5%, RRR +4.3%, ACTG +4.1%, CVS +4%, OZM +4%, LDL +3.9%, GRMN +3.8%, ADP +3.5%, ACHC +3.4%, CHK +3.4%, OCN +3.1%, DIN +3%, SODA +2.8%, TCP +2.7%, HCLP +2.5%, CBRE +2.4%, ABC +2.2%, INSM +2.2%, VOYA +2.1%, AMRN +2.1%, TDOC +2%, DVN +1.6%, GIB +1.6%, HRS +1.5%, GLUU +1.1%, WNC +1.1%, NI +1%

M&A news:

  • HCHC +69.8% (announces BeneVir Biopharm to be acquired by Janssen Biotech). 

Select AAPL related names showing strength:

  • CRUS +3.2%, SWKS +1.9%, QRVO +1.5%, FNSR +1.1%, AVGO +0.7%, . 

Other news:

  • TRVN +10.5% (Trevana and Jiangsu Nhwa Pharma enter an exclusive license agreement for the development and commercialization of Trevena's investigational product oliceridine)
  • SIGA +10.4% (SIGA Technologies announces a 'favorable' outcome of the FDA Antimicrobial Drugs Advisory Committee meeting on oral TPOXX)
  • RGNX +2.2% (given FDA Fast Track designation for RGX-121 Gene Therapy)
  • IAC +1.6% (following afternoon sell-off on FB dating app news)
  • MTCH +1.5% (following afternoon sell-off on FB dating app news)
  • PEP +0.9% (PepsiCo affirms increased dividend - previously announced increase in its annualized dividend)

Analyst comments:

  • IRWD +1.9% (upgraded to Buy from Neutral at Mizuho)
  • FCX +1.7% (upgraded to Sector Outperform at CIBC)